Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
22 Februar 2022 - 2:11PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February
2022
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Chair succession planning update and Annual Report
22 February 2022 11:00 GMT
Update on Succession Planning for Chair of the Board and
Publication of Annual Financial Report
AstraZeneca PLC (the Company) announced today that Leif Johansson,
Non-Executive Chair of the Board, intends to retire from the Board
at the conclusion of the Company's Annual General Meeting (AGM) in
2023.
Mr
Johansson was first elected to the Board in April 2012 and reached
nine years' tenure as a Director in April 2021. Last year, the
Board asked him to seek re-election at the 2021 AGM to lead the
Board's oversight of completion of the acquisition of Alexion.
Again this year, the Board believes it would be in the best
interests of shareholders for Mr Johansson to seek re-election at
the AGM in April 2022 and continue to serve as Chair for one
further year, to facilitate succession planning and the transition
to a new Chair.
The
search for a new Chair is proceeding well, led by Philip Broadley,
senior independent Non-Executive Director.
The
Company also announced today the publication of its Annual Report
and Form 20-F Information 2021 (the Annual Report).
A copy of the Annual Report has been submitted to
the National Storage Mechanism and will shortly be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Annual Report is also available on the
Company's website at: www.astrazeneca.com/annualreport2021.
The
Annual Report will be dispatched to shareholders in due
course.
The
Company's AGM will take place on 29 April 2022. The Notice of AGM
and Shareholders' Circular will be published and distributed to
shareholders in due course.
EXPLANATORY NOTE
For the purposes of complying with the Disclosure and Transparency
Rules (DTR) and the requirements imposed on issuers through the
DTRs, the Annual Report, as submitted to the National Storage
Mechanism, contains the following regulated information in unedited
form:
-
The
principal risks and uncertainties facing the
Company;
-
The
Directors' responsibility statement made in respect of the
Financial Statements and Directors' Report contained in the Annual
Report; and
-
A
statement regarding related party transactions.
A
copy of the Annual Report is available on the Company's website and
has also been submitted to the National Storage Mechanism, where it
will shortly be available for inspection.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in Oncology,
Rare Disease, and BioPharmaceuticals, including Cardiovascular,
Renal & Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
22 February
2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
